IGF1R is expressed in many types of cancer cells, including NSCLC [18], and enhanced activation of IGF1R is implicated in resistance to chemotherapy and targeted therapies such as EGFR-TKIs [19], [20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.